» Articles » PMID: 30132138

Involvement of Glutamate Receptors of the Paragigantocellularis Lateralis Nucleus in the Pain Modulatory Effect of 17β-estradiol in Male Rats

Overview
Publisher Springer
Specialty Neurology
Date 2018 Aug 23
PMID 30132138
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The pain modulatory role of the paragigantocellularis lateralis nucleus (LPGi) and the 17β-estradiol has thoroughly been probed. This study investigates the contribution of ionotropic glutamate receptors in pain modulatory effect of intra-LPGi injection of 17β-estradiol. For this purpose, the LPGi nucleus cannulation was performed and drugs were injected into this nucleus, 15 min prior to the formalin test. The duration of formalin-induced flexing and licking behaviors was recorded for 60 min immediately after formalin injection. The results showed that the flexing behavior is significantly decreased by intra-LPGi injection of 0.8 µmol 17β-estradiol duringboth phases of formalin test (P < 0.001). However, 17β-estradiol attenuated the licking duration only in the second phase (P < 0.001). Interestingly, NMDA and AMPA/kainate receptor antagonists (AP5 and CNQX, respectively) significantly counteracted the analgesic effect of intra-LPGi injection of 17β-estradiol in both phases of the formalin test (P < 0.001). Consequently, the revealing results showed that the analgesic effect of intra-LPGi injection of 17β-estradiol on acute inflammatory pain might be mediated via the activation of ionotropic glutamate receptors.

Citing Articles

Comparison of pain modulatory effect of the LPGi estragon receptor on inflammatory pain between pro-estrus and estrus phases and OVX rats.

Ansari S, Khahpay R, Khakpai F, Heidarzadeh Z, Khojasteh S Psychopharmacology (Berl). 2024; 242(1):129-147.

PMID: 39180591 DOI: 10.1007/s00213-024-06653-2.


An interaction between basolateral amygdala orexinergic and endocannabinoid systems in inducing anti-nociception in the rat formalin test.

Deli S, Bonab S, Khakpay R, Khakpai F, Feyzi M Psychopharmacology (Berl). 2022; 239(10):3171-3184.

PMID: 35918531 DOI: 10.1007/s00213-022-06199-1.